Introduction
In the last paragraph of the introduction (page 6), the relevance, aims and methods of the study are intertwined and unclear. Lines 10-14: the method of data collection for this study seems inappropriate here. Lines 14-18: looks like the aim of the study, please clearly state "the aim of the current study is…" and also mention that the aim was not only categorising, but also describing the three groups Materials and methods:
In general, the methodological steps of this study are not fully clear. For the first methodological step, it seems that the three groups were defined mostly based on survival, by clinician review. However, it is unclear how criteria other than survival were weighted in their review.
For the second methodological step, it seems that the authors aimed to statistically describe the incidence, prevalence and mortality of cancer survivors in the three groups. Although quality of data is questionable and results are only estimates, please clearly describe what statistical methods were used, and the number of cancer survivors included in the study.
Please clarify paragraph 4 and 5 (page 10); was this review process part of step one (defining the three groups), or was it used to describe the three groups as shown in table 2 (a third methodological step)?
Results:
Figure 1: this graph, combining one-and five-year survival, is hard to read. Consider including only five-year survival in this figure, and describe the results accordingly. Also, insert a caption for the X-axis.
Figure 2: Please use either bar-or pie-charts to clearly show the proportions of cancer survivors for incidence, prevalence and mortality separately, and include the patients that were not allocated to the three groups as a separate category. 
REVIEWER
Kate Rendle National Cancer Institute, USA REVIEW RETURNED 22-May-2017
GENERAL COMMENTS
With the growing number of cancer survivors, there is great need to understand how to better improve the long-term care of cancer patients while reducing the burden on the healthcare system. This manuscript proposes a novel approach to grouping the top 20 most common cancers in the UK into three groups using one-and fiveyear survival as a proxy for care needs. While important, the manuscript has several minor to moderate weaknesses that could be improved to increase scientific and clinical utility.
1. The most substantial criticism is that the grouping is driven primarily, if not solely, by survival rates. While the authors acknowledge other factors, in the end, the three groups are differentiated by "longer-term survival, intermediate survival, and shorter-term survival.
While key to long term care and support, this conceptualization misses the complexity of follow-up care (including co-morbidities, patient preferences, treatment regimen etc.). Additionally, it is likely that patients and clinicians are already using long-term survival to guide care pathways, so I am not sure how much this grouping will advance the actual practice of long-term care planning. As written, the results support a framing that identifies survival rates across cancers rather than tailoring care.
2. In Table 2 , the authors summarize the three groups and list "possible key concerns and interventions" to support care in each group using feedback from clinicians. While input from clinical stakeholders is important, this table leaves many questions and could be greatly enhanced by increasing references to extant literature on survivorship care (in discussion) and incorporating patient feedback. What do the authors conceive as next steps for this model? How would it explicitly alter or guide practice decisions or referral patterns? More is needed here to understand how the authors believe the model can be translated into tailored care.
3. Related to the above points, the authors presented the initial findings to a range of providers in different contexts, which is a strength of the article. However, the authors did not gather feedback from patients, whose care would be directly impacted if these groupings are translated into care decisions. This would greatly enhance the credibility of the groups and point to any potential challenges to implementing these groupings in practice.
4. The authors include categorizing 200+ cancers as the aim of the study, but in the analysis, they only categorize the top 20 most common cancers. I think this is reasonable, but references to 200+ should be revised to avoid reader confusion.
5. The authors use several reports from Macmillian to establish prevalence and other important statements in the manuscript. For a reader that is not familiar with Macmillian, it would helpful to include a bit of information on the NCRAS prevalence project (methods, aims, etc) and other reports to help evaluate rigor and validity of estimates. Also, additional peer-reviewed literature (preferably not authored by authors) should be added whenever possible.
REVIEWER

Rebecca Selove
Tennessee State University, Nashville TN USA REVIEW RETURNED 23-May-2017
GENERAL COMMENTS
I think this is an important article, and I recommend it be published with minor changes. I appreciate your description of the steps you took to arrive at the three groups. I wonder if my ideas about placements of commas and hyphens reflect US customs and conventions, and if the manuscript is written in a way that is more typical for the UK and Europe.
The reviewer also provided a marked copy with additional comments. Please contact the publisher for full details.
REVIEWER
Dori Klemanski OSUCCC -The James United States of America REVIEW RETURNED 24-May-2017
GENERAL COMMENTS
Thank you for allowing me to review this manuscript. It is well-written and a novel concept in stratifying cancer survivors/patients. My overall comment is that the stratification is heavily focused on prognosis, physical well-being and health rather than incorporating additional variables (e.g., psychosocial or practical factors) that could impair or contribute to alterations in care planning. Are there plans to incorporate or consider a holistic assessment to determining care needs?
VERSION 1 -AUTHOR RESPONSE Regarding Belle de Rooij's comments:
Comment:
"Lines 16-18: please describe the number of cancer survivors included in the study"
Response:
In answer to your request that the authors describe the number of cancer survivors included in the study we have included a statement regarding the population size of those described by the study in the abstract "Setting and participants". However, we are reluctant to use the term "cancer survivors" specifically, as this can mean a range of things, when linked to the chance of recurrence it can be hard to quantify and is not always recognised as useful by people living with cancer*****. Instead we prefer to talk in terms of people living with a cancer diagnosis as this is relatively clear.
Comments: -"Lines 31-34: This sentence seems inappropriate here. Please be more concise describing the two (?) methodological steps of this study (1, defining the groups by review and 2, statistically describing the incidence, prevalence and mortality of the groups)." -"In the last paragraph of the introduction (page 6), the relevance, aims and methods of the study are intertwined and unclear." -"Lines 10-14: the method of data collection for this study seems inappropriate here" -"Lines 14-18: looks like the aim of the study, please clearly state "the aim of the current study is…" and also mention that the aim was not only categorising, but also describing the three groups" -"In general, the methodological steps of this study are not fully clear. For the first methodological step, it seems that the three groups were defined mostly based on survival, by clinician review. However, it is unclear how criteria other than survival were weighted in their review." -"For the second methodological step, it seems that the authors aimed to statistically describe the incidence, prevalence and mortality of cancer survivors in the three groups. Although quality of data is questionable and results are only estimates, please clearly describe what statistical methods were used, and the number of cancer survivors included in the study." -"Please clarify paragraph 4 and 5 (page 10); was this review process part of step one (defining the three groups), or was it used to describe the three groups as shown in table 2 (a third methodological step)?"
Response: Thank you for highlighting the potential improvement in the order of methodological steps throughout the paper. The authors have adjusted for this, both in the "Primary and secondary outcome measures" section of the abstract and also in the "Materials and Methods" section in the main body of the paper for clarity. In the latter, the authors have addressed your suggestions that we enhance the separation of the relevance, aims (page 6) and methods of the study and that the calculations that went into this work are fully described (pages 7-9), which has added further coherence to this.
Comment: "Lines 37-44: please describe the group labels, and describe either one-or five-year survival, not both"
Response Thank you for feedback on inclusion of both 1-and 5-year survival within the "Results" section of the abstract. The authors have amended this to only include 5-year survival numbers in order to simplify the message in the abstract. However, in the abstract we use descriptions that refer to 1-year survival and in the main results we have kept the discussion of both 1-and 5-year survival. Response: Thank you for your suggested improvement to Table 2 , through its inclusion in the "Results" section of the paper rather than "Discussion". Our second reviewer, Kate Rendle, suggested that this could be strengthened by increasing references to extant literature. As we have accepted this comment, the authors feel that these adjustments make Table 2 "s inclusion within the "Discussion" section more fitting as it summarises the key results and adds context from the academic literature.
Comments: -" Figure 1 : this graph, combining one-and five-year survival, is hard to read. Consider including only five-year survival in this figure, and describe the results accordingly." -" Figure 2 : Please use either bar-or pie-charts to clearly show the proportions of cancer survivors for incidence, prevalence and mortality separately, and include the patients that were not allocated to the three groups as a separate category."
The authors have amended Figure 2 based upon your helpful recommendation to use a bar chart to increase clarity. For Figure 1 , we explored alternative graphical representations but concluded that the original Figure 1 submission is clearer at demonstrating the differences between the Three Cancer Groups and exploring the relationship between 1-and 5-year survival.
